Dova Pharmaceuticals, Inc.

15 articles with Dova Pharmaceuticals, Inc.

• 

  Approved! FDA gives Dova Pharma’s Doptelet a Thumbs Up

  5/22/2018

  Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
• 

  Three Companies with FDA Decisions in the Next Week

  5/15/2018

  There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.

• Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 15, 2018

  2/13/2018

  To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 7796295 five to 10 minutes before the start of the call.

• Dova Pharmaceuticals Announces the Appointment of Mark W. Hahn as CFO

  1/30/2018

  Mark will officially commence in his role as Chief Financial Officer of Dova on January 31st, 2018.

• Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag NDA With Priority Review

  11/28/2017

  The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is May 21, 2018.

• Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results

  11/10/2017

  Dova reported a net loss of $9.7 million for the third quarter of 2017, compared to a net loss of $7.2 million for the same period in 2016.

• Dova Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 9, 2017

  11/3/2017

  A question-and-answer session will follow Dova's remarks.

• Dova Pharma To Present Phase III Avatrombopag Data At The 2017 Liver Meeting Of The American Association For The Study Of Liver Diseases (AASLD)

  10/11/2017

• Dova Pharma Announces New Drug Application Submission To FDA For Avatrombopag, A Second Generation Thrombopoietin Receptor Agonist

  9/22/2017

• Dova Pharma Reports Second Quarter 2017 Operating and Financial Results

  8/11/2017

• Dova Pharma To Announce Second Quarter 2017 Financial Results on August 10, 2017

  8/4/2017

• Dova Pharma Targets A 9-Figure Opportunity, But Should You Buy Its IPO?

  6/30/2017

• Dova Pharma To Ring The Nasdaq Stock Market Opening Bell In Celebration Of Its IPO

  6/29/2017

• Dova Pharma Announces Pricing Of Initial Public Offering

  6/29/2017

• Dova Pharma Announces Hiring Of CEO And Presentation At The 35th Annual J.P. Morgan Healthcare Conference

  1/6/2017